[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 994
Citations 0
Comment and Response
August 7, 2013

BRAF V600E Mutation and Papillary Thyroid Cancer

Author Affiliations
  • 1Laboratory of Molecular Biology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
  • 2Scientific Directorate, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
  • 3Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
JAMA. 2013;310(5):534. doi:10.1001/jama.2013.8589

To the Editor The study by Dr Xing and colleagues1 explored the association between the BRAF V600E mutation and mortality in patients with papillary thyroid cancer (PTC) in a large retrospective cohort of 1849 patients from 13 centers worldwide. The authors concluded that the BRAF mutation was significantly associated with cancer-related mortality.

First Page Preview View Large
First page PDF preview
First page PDF preview
×